Abstract
Unlike the more commonly used diuretics, aquaretic agents can induce an increase in urinary volume without incurring a loss of electrolytes. These molecules belong to a family of vasopressin receptor antagonists, V2 in particular, that regulate optional renal water re-absorption via the synthesis and expression of aquaporin-2. In view of their properties, they have become the agent of choice in the treatment of hyponatremic states with water retention, and different studies have demonstrated that they are more effective and practical to use than other traditional approaches in the treatment of diseases such as cirrhosis-related ascites, SIADH and, above all, heart failure. However, the future probably holds the promise of new and unexpected applications for this type of drug in the treatment of several conditions, including polycystic kidney and glomerular disease, glaucoma and Menieres syndrome.
Keywords: Aquaretic, hyponatremia, heart failure, vasopressin, V2 antagonists
Current Pharmaceutical Design
Title: Aquaretic Agents: Whats Beyond the Treatment of Hyponatremia?
Volume: 13 Issue: 8
Author(s): Davide Bolignano, Giuseppe Coppolino, Manila Criseo, Susanna Campo, Adolfo Romeo and Michele Buemi
Affiliation:
Keywords: Aquaretic, hyponatremia, heart failure, vasopressin, V2 antagonists
Abstract: Unlike the more commonly used diuretics, aquaretic agents can induce an increase in urinary volume without incurring a loss of electrolytes. These molecules belong to a family of vasopressin receptor antagonists, V2 in particular, that regulate optional renal water re-absorption via the synthesis and expression of aquaporin-2. In view of their properties, they have become the agent of choice in the treatment of hyponatremic states with water retention, and different studies have demonstrated that they are more effective and practical to use than other traditional approaches in the treatment of diseases such as cirrhosis-related ascites, SIADH and, above all, heart failure. However, the future probably holds the promise of new and unexpected applications for this type of drug in the treatment of several conditions, including polycystic kidney and glomerular disease, glaucoma and Menieres syndrome.
Export Options
About this article
Cite this article as:
Bolignano Davide, Coppolino Giuseppe, Criseo Manila, Campo Susanna, Romeo Adolfo and Buemi Michele, Aquaretic Agents: Whats Beyond the Treatment of Hyponatremia?, Current Pharmaceutical Design 2007; 13 (8) . https://dx.doi.org/10.2174/138161207780363040
DOI https://dx.doi.org/10.2174/138161207780363040 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ribozyme- and Deoxyribozyme-Strategies for Medical Applications
Current Drug Targets Intra-Graft Abciximab and Verapamil Combined with Direct Stenting is a Safe and Effective Strategy to Prevent Slow-flow and No-Reflow Phenomenon in Saphenous Vein Graft Lesions not Associated with Thrombus
Recent Patents on Cardiovascular Drug Discovery Novel Anti-Arrhythmic Drugs for Atrial Fibrillation Management
Current Vascular Pharmacology Review of the Contribution of Radiolabelled Tracers for Tumour Cell Status Imaging
Current Medical Imaging Antibiotic Treatment in Native Valve Infective Endocarditis
Infectious Disorders - Drug Targets MicroRNA-21: From Cancer to Cardiovascular Disease
Current Drug Targets Paclitaxel (Taxol) and Taxoid Derivates for Lung Cancer Treatment: Potential for Aerosol Delivery
Current Cancer Drug Targets Immunoregulation Through 1,25-Dihydroxyvitamin D 3 and its Analogs
Current Drug Targets - Inflammation & Allergy Tocotrienols Regulate Bone Loss through Suppression on Osteoclast Differentiation and Activity: A Systematic Review
Current Drug Targets Kounis Syndrome Following Beta-Lactam Antibiotic Use: Review of Literature
Inflammation & Allergy - Drug Targets (Discontinued) Dietary Approaches and Alternative Therapies for Polycystic Ovary Syndrome
Current Nutrition & Food Science Insulin Resistance the Link between T2DM and CVD: Basic Mechanisms and Clinical Implications
Current Vascular Pharmacology Adamantane – A Lead Structure for Drugs in Clinical Practice
Current Medicinal Chemistry The Adipose Tissue as a Source of Vasoactive Factors
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Future Perspectives in the Pharmacological Treatment of Atrial Fibrillation and Ventricular Arrhythmias in Heart Failure
Current Pharmaceutical Design Acute Cerebral Blood Flow Variations after Human Cardiac Arrest Assessed by Stable Xenon Enhanced Computed Tomography
Current Neurovascular Research Gastroduodenal Disorders in Patients with CVID Undergoing Immunoglobulin Therapy
Current Pharmaceutical Biotechnology Novel Strategies for the Detection of Systolic and Diastolic Heart Failure
Current Cardiology Reviews A Review of Hypertension Management in Atrial Fibrillation
Current Hypertension Reviews Treating Heart Failure with Preserved Ejection Fraction Related to Arterial Stiffness. Can we Kill Two Birds With One Stone?
Current Vascular Pharmacology